ATNX

Athenex, Inc. (ATNX) | Rumor.io

Athenex

ATNX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ATNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 16

$ATNX may experience a price increase as it broke below its lower Bollinger Band.
The author expects a 50% bounce in the company's stock, citing a trend in banking stocks.
The post suggests that $ATNX is a potentially good trade for the week.

Generated by AI

Sentiment

Of the messages about ATNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· May 5

$ATNX has the potential to break through key resistance levels at $5.80 and $6.00, potentially leading to significant price appreciation.
The company's acquisition of Kuur Therapeutics is expected to expand its cell therapy capabilities, which could drive growth and increase the stock's value.
Athenex shares are trading higher, with some analysts predicting the stock could reach $12 or more, driven by its strong fundamentals and potential for future growth.

Bearish· Mar 2

Multiple analysts have downgraded Athenex's stock, including JP Morgan, Truist, SVB Leerink, and Oppenheimer, citing concerns about the company's valuation and profitability.
Athenex's stock price has been negatively impacted by delays in Oraxol's clinical trials, with investors waiting for future disclosures to drive the stock's performance.
The company's historical negative profitability levels may be a challenge to overcome, particularly if Athenex struggles to appease the FDA, leading to a reevaluation of its market value.

Generated by AI

Topics

Of the messages about ATNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Earnings· Nov 9

Athenex beats on revenue in Q3, according to pre-market reports.
The company has raised its revenue guidance following Q3 results.
Athenex reported its Q3 results, with details available for $ATNX.

Announcements· May 15

Athenex, Inc. (ATNX) filed for Chapter 11 bankruptcy, leading to a 52% share price decline.
The company has reached an agreement with lenders to pursue an expedited sales process for its assets, including its natural killer cell therapy unit.
ATNX shares have experienced significant price movements, increasing by 10.04% and 14.59% in response to the news of the agreement with lenders.

Technical Analysis· Mar 26

ATNX has triggered multiple technical alerts, including a Non-ADX 1,2,3,4 Bullish signal.
The alerts suggest a potential bullish trend for ATNX.
Further analysis is required to confirm the validity of these alerts.

Generated by AI

Community

Of the messages about ATNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	—
Newcomers	—	—	—	—

Regulars· May 16

The price of ATNX may be increasing as it broke below the lower Bollinger Band, a potential indicator of a climb.

Newcomers· May 16

New to $ATNX, one user notes the potential for a 50% bounce in the stock's price.
Some newcomers are banking on a continuation of the trend in ATNX, Inc.
ATNX is seen as a stock where we've yet to see a specific type of event occur.

Generated by AI

Also Discussed

Investors talking about ATNX also mention

#	Name	Attention
1	KMPH - KemPharm, Inc.	——
2	JNCE - Jounce Therapeutics, Inc.	——
3	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
4	GTHX - G1 Therapeutics, Inc.	——
5	CorMedix Inc.CRMD	0%+0
6	AGRX - Agile Therapeutics, Inc.	——
7	Avenue Therapeutics Inc.ATXI	0%new
8	Intrusion Inc.INTZ	0%0
9	ALBO - Albireo Pharma, Inc.	——
10	LHCG - LHC Group, Inc.	——

Athenex, Inc.

Location

Social

What share of all stock conversation is about ATNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 16

$ATNX may experience a price increase as it broke below its lower Bollinger Band.
The author expects a 50% bounce in the company's stock, citing a trend in banking stocks.
The post suggests that $ATNX is a potentially good trade for the week.

Generated by AI

Sentiment

Of the messages about ATNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· May 5

$ATNX has the potential to break through key resistance levels at $5.80 and $6.00, potentially leading to significant price appreciation.
The company's acquisition of Kuur Therapeutics is expected to expand its cell therapy capabilities, which could drive growth and increase the stock's value.
Athenex shares are trading higher, with some analysts predicting the stock could reach $12 or more, driven by its strong fundamentals and potential for future growth.

Bearish· Mar 2

Multiple analysts have downgraded Athenex's stock, including JP Morgan, Truist, SVB Leerink, and Oppenheimer, citing concerns about the company's valuation and profitability.
Athenex's stock price has been negatively impacted by delays in Oraxol's clinical trials, with investors waiting for future disclosures to drive the stock's performance.
The company's historical negative profitability levels may be a challenge to overcome, particularly if Athenex struggles to appease the FDA, leading to a reevaluation of its market value.

Generated by AI

Topics

Of the messages about ATNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Earnings· Nov 9

Athenex beats on revenue in Q3, according to pre-market reports.
The company has raised its revenue guidance following Q3 results.
Athenex reported its Q3 results, with details available for $ATNX.

Announcements· May 15

Athenex, Inc. (ATNX) filed for Chapter 11 bankruptcy, leading to a 52% share price decline.
The company has reached an agreement with lenders to pursue an expedited sales process for its assets, including its natural killer cell therapy unit.
ATNX shares have experienced significant price movements, increasing by 10.04% and 14.59% in response to the news of the agreement with lenders.

Technical Analysis· Mar 26

ATNX has triggered multiple technical alerts, including a Non-ADX 1,2,3,4 Bullish signal.
The alerts suggest a potential bullish trend for ATNX.
Further analysis is required to confirm the validity of these alerts.

Generated by AI

Community

Of the messages about ATNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	—
Newcomers	—	—	—	—

Regulars· May 16

The price of ATNX may be increasing as it broke below the lower Bollinger Band, a potential indicator of a climb.

Newcomers· May 16

New to $ATNX, one user notes the potential for a 50% bounce in the stock's price.
Some newcomers are banking on a continuation of the trend in ATNX, Inc.
ATNX is seen as a stock where we've yet to see a specific type of event occur.

Generated by AI

Athenex

Social

May 16

Sentiment

Bullish· May 5

Bearish· Mar 2

Topics

Earnings· Nov 9

Announcements· May 15

Technical Analysis· Mar 26

Community

Regulars· May 16

Newcomers· May 16

Also Discussed

Athenex, Inc.

Company Information

Location

Social

May 16

Sentiment

Bullish· May 5

Bearish· Mar 2

Topics

Earnings· Nov 9

Announcements· May 15

Technical Analysis· Mar 26

Community

Regulars· May 16

Newcomers· May 16

Also Discussed